Current Report Filing (8-k)
October 22 2021 - 4:17PM
Edgar (US Regulatory)
0001173281
false
0001173281
2021-10-22
2021-10-22
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date of report (Date of earliest event reported):
October 22, 2021
NeuBase Therapeutics, Inc.
(Exact Name of Registrant as Specified in Its
Charter)
Delaware
|
|
001-35963
|
|
46-5622433
|
(State
or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S.
Employer
Identification No.)
|
350 Technology Drive,
Pittsburgh,
PA
|
|
15219
|
(Address
of Principal Executive Offices)
|
|
(Zip Code)
|
|
(646)
450-1790
|
|
|
(Registrant’s
Telephone Number, Including Area Code)
|
|
|
N/A
|
|
|
(Former
Name or Former Address, if Changed Since Last Report)
|
|
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written communications pursuant
to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to
Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
Title
of each class
|
Trading
Symbol(s)
|
Name
of each exchange on which registered
|
Common Stock, par value $0.0001 per share
|
NBSE
|
The Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405) or Rule 12b-2 of the Securities Exchange Act
of 1934 (17 CFR § 240.12b-2).
Emerging growth company ¨
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 5.02.
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
|
On October 22, 2021, Kia Motesharei, the Chief Business and Strategy
Officer of NeuBase Therapeutics, Inc. (the “Company”), notified the Company of his intent to resign from the Company, effective
November 5, 2021. Dr. Motesharei’s resignation is not a result of any disagreement with the Company on any matter relating to the
Company’s policies or procedures.
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
NEUBASE THERAPEUTICS, INC.
(Registrant)
|
|
|
Date: October 22, 2021
|
By:
|
/s/ Dietrich Stephan
|
|
|
Dr. Dietrich A. Stephan
|
|
|
President, Chief Executive Officer, and Interim Chief Financial Officer
|
NeuBase Therapeutics (NASDAQ:NBSE)
Historical Stock Chart
From Mar 2024 to Apr 2024
NeuBase Therapeutics (NASDAQ:NBSE)
Historical Stock Chart
From Apr 2023 to Apr 2024